Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity

被引:57
作者
Mayo, KH
Dings, RPM
Flader, C
Nesmelova, I
Hargittai, B
van der Schaft, DWJ
van Eijk, LI
Walek, D
Haseman, J
Hoye, TR
Griffioen, AW
机构
[1] Univ Minnesota, Hlth Sci Ctr, Dept Biochem, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Mol Biol & Biophys, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA
[4] Univ Hosp Maastricht, Dept Pathol, Res Inst Growth & Dev, Angiogenesis Lab, NL-6202 AZ Maastricht, Netherlands
[5] Univ Hosp Maastricht, Dept Internal Med, Res Inst Growth & Dev, Angiogenesis Lab, NL-6202 AZ Maastricht, Netherlands
关键词
D O I
10.1074/jbc.M308608200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Based on structure-activity relationships of the angiostatic beta-sheet-forming peptide anginex, we have designed a mimetic, 6DBF7, which inhibits angiogenesis and tumor growth in mice. 6DBF7 is composed of a beta-sheet-inducing dibenzofuran (DBF)-turn mimetic and two short key amino acid sequences from anginex. This novel antiangiogenic molecule is more effective in vivo than parent anginex. In a mouse xenograft model for ovarian carcinoma, 6DBF7 is observed to reduce tumor growth by up to 80%. It is suggested that the activity is based on antiangiogenesis, because in vitro tube formation is inhibited, and because treatment of tumor-bearing mice led to a significant reduction in microvessel density within the tumor. This partial peptide mimetic is the first endothelial cell-specific molecule designed as a substitute for an angiostatic inhibitory peptide.
引用
收藏
页码:45746 / 45752
页数:7
相关论文
共 45 条
[11]  
Dings RPM, 2003, CANCER RES, V63, P382
[12]   Anti-tumor activity of the novel angiogenesis inhibitor anginex [J].
Dings, RPM ;
van der Schaft, DWJ ;
Hargittai, B ;
Haseman, J ;
Griffioen, AW ;
Mayo, KH .
CANCER LETTERS, 2003, 194 (01) :55-66
[13]  
DINGS RPM, 2003, IN PRESS ANGIOGENESI
[14]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[15]   Anginex, a designed peptide that inhibits angiogenesis [J].
Griffioen, AW ;
van der Schaft, DWJ ;
Barendsz-Janson, AF ;
Cox, A ;
Boudier, HAJS ;
Hillen, HFP ;
Mayo, KH .
BIOCHEMICAL JOURNAL, 2001, 354 :233-242
[16]   INHIBITION OF ENDOTHELIAL-CELL - PROLIFERATION BY PLATELET FACTOR-IV INVOLVES A UNIQUE ACTION ON S-PHASE PROGRESSION [J].
GUPTA, SK ;
SINGH, JP .
JOURNAL OF CELL BIOLOGY, 1994, 127 (04) :1121-1127
[17]   Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution [J].
Hohenester, E ;
Sasaki, T ;
Olsen, BR ;
Timpl, R .
EMBO JOURNAL, 1998, 17 (06) :1656-1664
[18]   Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 [J].
Jiménez, B ;
Volpert, OV ;
Crawford, SE ;
Febbraio, M ;
Silverstein, RL ;
Bouck, N .
NATURE MEDICINE, 2000, 6 (01) :41-48
[19]   STRUCTURE OF TUMOR NECROSIS FACTOR [J].
JONES, EY ;
STUART, DI ;
WALKER, NPC .
NATURE, 1989, 338 (6212) :225-228
[20]   Cell surface glypicans are low-affinity endostatin receptors [J].
Karumanchi, SA ;
Jha, V ;
Ramchandran, R ;
Karihaloo, A ;
Tsiokas, L ;
Chan, BD ;
Dhanabal, M ;
Hanai, J ;
Venkataraman, G ;
Shriver, Z ;
Keiser, N ;
Kalluri, R ;
Zeng, HY ;
Mukhopadhyay, D ;
Chen, RL ;
Lander, AD ;
Hagihara, K ;
Yamaguchi, Y ;
Sasisekharan, R ;
Cantley, L ;
Sukhatme, VP .
MOLECULAR CELL, 2001, 7 (04) :811-822